XTalks

NOVEMBER 22, 2022

Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US. As part of the deal, Sanofi will pay $35 million to Provention along with another $20 million to secure the right to first negotiation on exclusive global marketing rights when Tzield is approved in other countries.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

FEBRUARY 2, 2023

The US Food and Drug Administration (FDA) has recently cleared for marketing an app called Tidepool Loop which can be used with compatible devices for automated insulin dosing (AID). The Tidepool loop app involves three integral parts: an integrated continuous glucose monitor (iCGM), a controller and an insulin pump.

Insulin 52

Insulin Marketing Life Science Development 52

XTalks

DECEMBER 14, 2022

CGMs can alert diabetics sufficiently in advance of too high or low blood glucose levels, allowing the wearer to improve the situation with insulin, for example. Many CGM devices are on the market and are relatively accurate and easy to use. Dexcom, Inc. , a cellphone) every five minutes.

Insulin 98

Insulin Marketing Branding Life Science 98

XTalks

JANUARY 16, 2025

Linsitinib, an oral small molecule that targets the insulin-like growth factor-1 receptor (IGF-1R), is designed to address the underlying mechanisms driving thyroid eye disease. It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JULY 15, 2024

Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Avexitide differs from the current lot of GLP-1s on the market, which are agonists of the GLP-1 receptor. This action helps mitigate hypoglycemia by reducing insulin secretion and stabilizing glucose levels.

Drugs 52

Drugs Insulin Life Science Marketing 52

XTalks

JULY 15, 2024

Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Avexitide differs from the current lot of GLP-1s on the market, which are agonists of the GLP-1 receptor. This action helps mitigate hypoglycemia by reducing insulin secretion and stabilizing glucose levels.

Insulin 52

Insulin Drugs Life Science Marketing 52

XTalks

OCTOBER 22, 2021

In July 2021, the agency approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn) for the treatment of diabetes. Semglee is both biosimilar to, and interchangeable with, Lantus (insulin glargine). Cyltezo and the Emerging Humira Biosimilars Market.

FDA Approval 98

FDA Approval Production Insulin Antibody 98

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.

Drugs 130

Drugs Gene Therapy Regulation Insulin 130

XTalks

NOVEMBER 3, 2022

Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1). In its first quarter on the market since its approval, sales totalled $97 million between July and September in the US.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

JANUARY 25, 2023

TheracosBio will thus be going up against some major market competition. XTALKS WEBINAR: Review of Key Trends for Life Science Commercial Teams in 2023 Register for this free on-demand webinar to learn about the latest trends in sales and marketing campaigns that could help bolster commercial success for life science companies this year.

FDA Approval 52

FDA Approval Drugs Life Science Cosmetics 52

XTalks

FEBRUARY 6, 2024

Fractyl Health’s common stock commenced trading on the Nasdaq Global Market under the ticker symbol “GUTS” on February 2, 2024. Revita, an outpatient endoscopic procedural therapy, which aims to eliminate insulin needs and enhance glycemic control by ablating dysfunctional duodenal mucosa.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

APRIL 29, 2022

These bind to their respective receptors to increase glucose metabolism by increasing insulin secretion. The promising trial results could pose a threat to Danish drugmaker Novo Nordisk’s GLP-1 agonist drug Wegovy (semaglutide), which has dominated the obesity drug market since its launch in 2021. billion in 2020 to $5.42 percent.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

FEBRUARY 21, 2024

Recently, Eli Lilly revealed promising results from a mid-stage trial, indicating that its popular drug, tirzepatide (marketed as Zepbound and Mounjaro for weight loss and diabetes, respectively), may be an effective treatment for the fatty liver disease metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

Pharma in Brief

AUGUST 9, 2021

The proposed amendments are intended to modernize the Canadian therapeutic product regulatory system at every stage of products’ lifecycles from authorization to post-market. Individual standards for certain biologic drugs ( e.g. , insulin) would be repealed in favor of relying on the standards set out in Schedule B to the Food and Drugs Act.

Regulation 98

Regulation Drugs Manufacturing Production 98

pharmaphorum

OCTOBER 2, 2020

You don’t really think of TikTok and B2B marketing together, but why not? Beyond this, there are other factors within the control of the healthcare and life sciences industries that will determine how ubiquitous self care actually becomes. You don’t really think of TikTok and B2B marketing together, but why not?

Regulation 111

Regulation Doctors Doctor Production 111

XTalks

FEBRUARY 14, 2024

On the other hand, Republican senators largely defended the CEOs and the free market. Currently, in the US, three PBMs control 80 percent of the market. Some Senators were skeptical and wondered why there would be such a complex system that no one understands it. The companies are often integrated with pharmacies and insurers.

Drugs 52

Drugs Insulin Pharmacy Development 52

XTalks

OCTOBER 11, 2023

Rybelsus is Novo’s third semaglutide product on the market, a tablet form of the drug used for the treatment of type 2 diabetes. They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

XTalks

APRIL 29, 2021

This insight into patient symptoms and quality of life can also inform label claims on the approved product, as well as provide valuable information on how to adapt to specific geographical markets.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Drugs 95

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. The marketing rights to Thiola were acquired by Retrophin in 2014 from Mission Pharmacol.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

JUNE 12, 2023

Medtronic’s Hugo Robotic-Assisted Surgery system , released in a limited market in June 2021, has been receiving positive reviews for its performance in various surgeries. Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. It also plans to launch these products in the US. percent from $27.06

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

JULY 4, 2024

We will also examine the rising stars like Novo Nordisk’s Ozempic (semaglutide), which has become a frontrunner in diabetes management, and the dynamic performance of Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in the HIV treatment landscape.

Sales 40

Sales Drugs FDA Approval Marketing 40

XTalks

NOVEMBER 21, 2024

Additionally, over a 176-week period, weekly injections of tirzepatide (marketed as Zepbound and Mounjaro) using pooled doses of 5 mg, 10 mg and 15 mg, significantly reduced the risk of disease progression to type 2 diabetes by 94 percent compared with placebo in adult prediabetes patients who were obese or overweight.

Sales 105

Sales Insulin Drugs Trials 105

XTalks

FEBRUARY 8, 2021

As biologics have the reputation of being expensive due to their complex nature and production, biosimilars have the ability to improve market access to patients and payors who would otherwise be unable to afford these drugs. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed.

Production 78

Production Insulin Branding Generic Drugs 78

Pharmaceutical Technology

DECEMBER 22, 2022

Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. The category includes any projects that demonstrate an innovative approach to the market. Civica JAAQ Sanofi.

Insulin 130

Insulin Production Development Genetics 130

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. billion in 2021 to $61.6 billion by 2030.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

AUGUST 30, 2024

This blog highlights the top 10 largest publicly traded pharma and biotech companies by market capitalization in 2024 , showcasing their influence and contributions to global health. Johnson & Johnson (JNJ) Market Capitalization: $402.1 Novo Nordisk (NVO) Market Capitalization: $377.2 MRK) Market Capitalization: $280.4

Marketing 98

Marketing Production Sales Antibody 98

XTalks

MAY 13, 2021

A recent report by Market Watch, based on data from a survey conducted by Hub Entertainment Research in November 2020, shows that the proportion of US consumers who said they were watching a lot more TV than they did prior to the pandemic remains unchanged since July 2020. And this trend doesn’t seem to be letting up any time soon.

Insulin 104

Insulin Marketing Drugs Branding 104

XTalks

OCTOBER 26, 2020

Autoantibody screening involves measuring levels of islet autoantibodies (iAb) that recognize antigens found in insulin-producing pancreatic beta cells. She said that’s why it’s “so important that we educate the market with campaigns like the ones we’ve launched.”

Insulin 98

Insulin Packaging Packaging Doctors 98

Delveinsight

JULY 21, 2021

Apart from the rich emerging pipeline, the other factors such as an increase in the prevalence population of Rheumatoid Arthritis, and an increase in the geriatric population are expected to contribute significantly to the Rheumatoid Arthritis Therapeutics Market. It is also known as insulin-dependent diabetes. Multiple Sclerosis (MS).

Pharma Companies 94

Pharma Companies Marketing Development Insulin 94

XTalks

FEBRUARY 2, 2023

Amgen’s Amjevita, the first biosimilar version of AbbVie’s blockbuster arthritis injection Humira (adalimumab), has finally hit the market this week after fetching US Food and Drug Administration (FDA) approval back in 2016. Following Amjevita, more than a handful of other Humira biosimilars will be flooding the market this year.

Marketing 52

Marketing FDA Approval Branding Drugs 52

Roots Analysis

MARCH 21, 2022

Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades. Subcutaneous biologics – current market landscape. Our Social Media Platform. Web: [link]. LinkedIn: [link].

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

Roots Analysis

SEPTEMBER 22, 2023

These significant benefits offered by wearable injectors, coupled with their rising demand in the pharmaceutical industry and healthcare sector, worldwide is likely to drive market growth during in the coming years. If the USFDA finds the product to be unsafe and ineffective, it may not get marketing approval.

Drug Delivery 40

Drug Delivery Marketing Insulin Drugs 40

The Pharma Data

APRIL 1, 2021

By fostering an environment where companies can invest and grow, leading life sciences firms like Sanofi are increasingly looking to this country to establish their manufacturing facilities,”. About Fluzone High-Dose Quadrivalent influenza vaccine.

Vaccination 52

Vaccination Vaccine Manufacturing Insulin 52

XTalks

MARCH 8, 2021

And now the tirzepatide results could help Lilly continue its market march if it wins approval for it. GLP-1 receptor agonists lower blood glucose levels by increasing the production of insulin. GLP-1 acts on GLP-1 receptors on insulin-producing pancreatic ? cells to stimulate insulin secretion. GLP-1 Receptor Agonists.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98